- Last week, Axsome Therapeutics Inc’s (NASDAQ:AXSM) major depression candidate received the much-awaited FDA approval.
- HC Wainwright notes that the approval comes roughly a year after the original Prescription Drug User Fee Act (PDUFA) decision date.
- Auvelity (dextromethorphan HBr-bupropion HCl, formerly AXS-05) is the first and only rapid-acting oral medicine approved for major depressive disorder with the labeling of statistically significant antidepressant efficacy compared to placebo starting at one week.
- Also Read: What SVB Says On Axsome’s Strategy Review On Sunosi For Sleeping Disorder.
- The analyst reiterates the Buy rating while raising the price target from $180 to $210.
- As pricing information for Auvelity is awaited, the analyst says that antidepressant agents with good efficacy data have historically experienced robust uptake and that the market remains a segment with high unmet need despite several having several generic agents.
- Boxed warning (specifying suicidal ideation and behaviors) will not be a significant barrier to broad market penetration.
- Price Action: AXSM shares are up 1.70% at $65.56 on the last check Tuesday.
Algonquin Power Q4 EPS $0.22 Misses $0.23 Estimate, Sales $748.00M Beat $703.54M Estimate
Algonquin Power (NYSE:AQN) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.23 by 4.35 percent. This is a 4.76 percent increase over earnings of $0.21 per share from the
